India tightens drug safety rules after global contamination scandals

India’s drug regulator has strengthened pharmacovigilance rules for pharmaceutical companies. The Central Drugs Standard Control Organisation (CDSCO) introduced stricter monitoring to improve drug safety and prevent public health risks. The move follows concerns over contaminated medicines linked to child deaths abroad. The CDSCO issued a circular requiring all drug manufacturers to set up and maintain effective pharmacovigilance systems. These systems must collect and report adverse drug reactions (ADRs) as part of routine safety checks. Regulators, including State Licensing Authorities (SLAs) and Union Territory officials, will now verify compliance during inspections.

The updated rules align with recent amendments to Schedule M, India’s Good Manufacturing Practices (GMP) guidelines. These changes bring local standards closer to global benchmarks set by the World Health Organization (WHO). Under the new norms, every licence holder must have a working pharmacovigilance system for ADR monitoring. The directive aims to boost post-marketing surveillance and detect harmful drug reactions early. A strong pharmacovigilance framework helps regulators spot safety risks faster, recall faulty products, and avoid large-scale health emergencies. The CDSCO has also stressed greater accountability for pharmaceutical firms in tracking drug safety.

The tightened pharmacovigilance rules come after reports of contaminated cough syrups causing child fatalities in other countries. Regulators will now enforce stricter checks on drug quality and post-market monitoring. Companies must comply with the updated norms to ensure patient safety and regulatory compliance.